Elucidation of the role of "Stress Granules" that can be therapeutic targets for cancer and ALS -- Kindai University
- Discovered for the first time in the world that Stress Granules (SGs) have the role of a "safety brake" that regulates signaling pathways that control cell proliferation, such as Protein Kinase C (PKC) and Mitogen-Activated Protein Kinase (MAPK). - SGs have the function of preventing excessive activation of MAPK by incorporating PKC.
Mechanism of the selective induction of cancer cell-specific cell death by ACA-28 - Kindai University
- Elucidation of the mechanism of the compound "ACA-28" that selectively induces cell death in cancer cells - ACA-28 induces cell death of cancer cells and inhibits the growth by destroying tumor suppressor factors. - Expectations for the development of anticancer drugs with less side effects that target brakes instead of accelerators for cancer cells
Efficacy of Opdivo (Nivolumab) in Cancer of Unknown Primary Cases Confirmed - Kindai University
- Efficacy of molecular target drug Nivolumab verified in investigator-initiated clinical trial for use with CUP by hospital team from Kindai University’s Faculty of Medicine - Reductions by more than half in tumor size in over 20% of CUP patients observed - Nivolumab expected to become standard treatment for CUP cases with no standard treatment
Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University
The research team from Kindai University's Faculty of Medicine, in cooperation with DAIICHI SANKYO COMPANY, LIMITED, have verified at the preclinical stage that using the currently under-development anti-cancer drug, U3-1402*1, in combination with immune checkpoint inhibitors*2 has the potential to be an effective treatment.
Ground Breaking Development of World’s First CurativeTreatment of Intractable Hepatocellular Carcinoma Path to Establishment of Standard Treatment of Hepatocellular Carcinoma - Kindai University
Senior Administrator Masatoshi Kudo of Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, with his research group has invented a new method (LEN-TACE) of treating patients with intractable multinodular or large liver cancers, particularly those with near advanced liver cancer.